Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Clinically isolated syndrome - Rethinking the diagnosis.
Cuprizone demyelination of the corpus callosum in mice correlates with altered social interaction and impaired bilateral sensorimotor coordination.
Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis.
ACRM I American Congress of Rehabilitation
Neuroprotective dimethyl fumarate synergizes with immunomodulatory interferon beta to provide enhanced axon protection in autoimmune neuroinflammation.
Firategrast: natalizumab in a pill?
MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study.
Delayed visual evoked response in optic neuritis.
Comparative efficacy of switching to natalizumab in active multiple sclerosis.
Suppressed RNA-Polymerase 1 Pathway Is Associated with Benign Multiple Sclerosis.
Optical coherence tomography reflects brain atrophy in MS: A four year study.
Oral BG-12 (dimethyl fumarate) significantly reduced multiple sclerosis (MS) relapses and disability progression in DEFINE Phase 3 clinical trial
Delta-9-tetrahydrocannabinol/cannabidiol (sativex(®)): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
215ON201 BIIB033 In Acute Optic Neuritis (AON) (RENEW)
Episode 17 with Dr. Hans Lassmann on the usefulness of animal models for studying multiple sclerosis.
Status spongiosus of CNS and hepatic changes induced by cuprizone (biscyclohexanone oxalyldihydrazone).
Multiple sclerosis, vitamin D, and HLA-DRB1*15.
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
Mitoxantrone - an anthraquinone antibiotic with antitumor activity applied for the treatment of multiple sclerosis.
National MS Society: Research Grants
Episode 35 with Dr. Daniel Reich on neuroradiology in MS
Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome.
Smoking and increased risk of multiple sclerosis: parallel trends in the sex ratio reinforce the evidence.

Pages